This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Eckert & Ziegler has entered into an agreement with Actinium Pharmaceuticals to supply the firm with the radioisotope actinium-225 (Ac-225). Actinium will continue developing its lead radiopharmaceutical product Actimab-A, as well as additional early and late-stage development candidates for both U.S.
Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine.
Blue Earth Diagnostics and Sinotau Pharmaceutical have signed an agreement to distribute Blue Earth's Posluma (flotufolastat F-18) PET radiotracer in China.
Food and Drug Administration (FDA) has approved Novartis' Lutathera (lutetium-177 [Lu-177]) DOTATATE radiopharmaceutical for treatment of pediatric patients who are 12 years old and older with somatostatin receptor (SSTR)-positive gastroentropancreatic neuroendocrine tumors (GEP-NETs).
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
facility NorthStar produces first Mo-99 batch at new facility NorthStar and Inhibrx ink deal on radiopharmaceutical development NorthStar completes construction of Mo-99 production facility Read more on AuntMinnie.com Related Reading: NorthStar appoints new president/CEO NorthStar installs accelerator at its new Wisc.
Fusion Pharmaceuticals announced a patent dispute settlement and new licensing agreement with Heidelberg University and Euratom for exclusive, worldwide rights to their existing patent for FPI-2265, an actinium-225-based targeted radiotherapy for the treatment of prostate-specific membrane antigen (PSMA)-expressing cancers.
Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Centers for Medicare and Medicaid (CMS) and manufacturers that agree to provide pharmaceuticals at significantly reduced rates for facilities that qualify.
Through this partnership, AtomVie secures access to Theralugand, which will spur more development of Lu-177-based radiopharmaceuticals in their facility.
Fusion Pharmaceuticals has secured clearance from the U.S. Read more on AuntMinnie.com Related Reading: Fusion heralds FDA tumor therapy clearance Fusion and Niowave ink $5M collaboration Fusion Pharmaceuticals to build radiopharma plant in Canada Fusion buys radiopharmaceutical from Ipsen Food and Drug Administratio.
Radiopharmaceutical developer Actinium Pharmaceuticals is highlighting six researc. Read more on AuntMinnie.com Related Reading: Actinium, Astellas to create actinium-225 radiotherapies Zevacor signs on as manufacturing partner for Actinium
Clarity Pharmaceuticals has secured fast-track designation from the U.S. Food and Drug Administration (FDA) for its copper-67 (Cu-67) SAR-bisPSMA radiopharmaceutical for treating advanced prostate cancer.
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.
NorthStar Medical Radioisotopes has launched its new radiopharmaceutical Contract Development and Manufacturing (CDMO) facility on its campus in Beloit, WI.
Food and Drug Administration (FDA) has granted Clarity Pharmaceuticals fast-track designation for its copper-64 (Cu-64) sarcophagine (SAR) bisPSMA radiopharmaceutical.
Read more on AuntMinnie.com Related Reading: NorthStar manufactures Cu-67 for Clarity Pharmaceuticals NorthStar appoints new president/CEO NorthStar installs accelerator at its new Wisc. facility NorthStar produces first Mo-99 batch at new facility NorthStar and Inhibrx ink deal on radiopharmaceutical development
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
Telix Pharmaceuticals plans to spin off its wholly-owned subsidiary Rhine Pharma and structure it as an independent company. Rhine Pharma’s mission will be to expand global access to radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m (Tc-99m) and rhenium-188 (Re-188), the company said.
TerraPower Isotopes has shipped its first samples of Actinium-225 (Ac-225) to two pharmaceutical companies to develop targeted cancer treatments in drug trials. Global demand for Ac-225 is expected to increase as more radiopharmaceutical treatments using Actinium-225 are developed, the company noted.
By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."
With her large experience in the pharmaceutical industry, Helen Blanco currently serves as Chief Operating Officer at Node Pharma , a preclinical radiopharmaceutical company based in Norway. Here is another excerpt from our conversation.
Telix Pharmaceuticals has inked a deal to acquire Florida-based radiopharmacy network RLS Radiopharmacies for up to $250 million, the companies announced. and distributes PET, SPECT, and therapeutic radiopharmaceuticals through 31 radiopharmacies across 18 states, Telix said. “By
Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, and PSI CRO, a global contract research organization, plan to conduct a trial using Clarity's phase III diagnostic trial of Clarify for prostate cancer patients.
Good Manufacturing Practices ensure the consistent quality, safety, and efficacy of pharmaceutical products through rigorous production standards. The post Overview of Good Manufacturing Practices (GMP) in Radiopharmaceuticals appeared first on Open MedScience.
With her large experience in the pharmaceutical industry, Helen Blanco currently serves as Chief Operating Officer at Node Pharma , a preclinical radiopharmaceutical company based in Norway. We recently spoke with Helen about the key criteria when selecting an imaging vendor and exciting upcoming innovations in the oncology space.
Lu-177 is a medical radioisotope frequently used in radiopharmaceutical therapy to treat cancer. This is a mandatory process needed to obtain pharmaceutical manufacturing authorization. ITM said with the RAM license and other regulatory approvals, the company has achieved operational readiness.
Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclear medicine. The post The Transformative Impact of Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.
By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."
Evans, a professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco, was recognized for his work in biomarker discovery and radiopharmaceutical development. He has published more than 90 peer-reviewed articles and is a co-inventor on 13 patents pending or issued.
He has more than 22 years of operational and commercial expertise in radioisotopes and radiopharmaceuticals. actinium-225 (Ac-225), and drive business development initiatives for NorthStar’s Radiopharmaceutical CDMO/CMO business units. Ac-225 and Cu-67 using environmentally preferable technologies. SPECT franchise.
milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., NorthStar’s commercialized, U.S.-based
BWXT Medical will collaborate closely with NorthStar, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, to streamline production processes, enhance safety protocols and innovate new methods of isotope generation.
ICH Q10 is a global model for managing pharmaceutical quality, ensuring compliance, continuous improvement, and risk manage The post The International Council for Harmonization (ICH) Q10: A Model for a Robust Pharmaceutical Quality Management System appeared first on Open MedScience.
milla1cf Mon, 04/24/2023 - 14:10 April 24, 2023 — - NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David , MBA, MS, as Vice President, Operations.
Marco Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc., Campione also joins the Blue Earth Diagnostics Ltd. Bracco Imaging S.p.A.,
Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.
Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Ac-225 and copper-67 (Cu-67) for advancing clinical research and commercial radiopharmaceutical therapy products. Ac-225 to Nucleus. The Company will use its electron accelerator technology to produce n.c.a.
milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 for use in radiopharmaceutical therapy (RPT). actinium-225 (Ac-225). “As a company at the forefront of U.S.
PanTera is committed to supporting the pharmaceutical industry by scaling up production to meet the significant global demand for targeted radiopharma-based therapeutics in the fight against cancer.”
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content